Skip to main content

3 Result(s)

within Anne Charlet Remove this filter

and

  1. Article

    Open Access

    The IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AML

    FLT3-ITD is the most predominant mutation in AML being expressed in about one-third of AML patients and is associated with a poor prognosis. Efforts to better understand FLT3-ITD downstream signaling to possib...

    Anne Charlet, Max Kappenstein, Philip Keye, Kathrin Kläsener, Cornelia Endres… in Leukemia (2022)

    Download PDF (2279 KB) View Article

  2. No Access

    Article

    Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo

    An important limitation of FLT3 tyrosine kinase inhibitors (TKIs) in FLT3-ITD positive AML is the development of resistance. To better understand resistance to FLT3 inhibition, we examined FLT3-ITD positive ce...

    Christoph Rummelt, Sivahari P. Gorantla, Manja Meggendorfer, Anne Charlet… in Leukemia (2021)

  3. No Access

    Article

    High platelet reactivity after P2Y12-inhibition in patients with atrial fibrillation and coronary stenting

    High platelet reactivity (HPR) after P2Y12-inhibition in patients undergoing coronary stenting is associated with an increased risk for thromboembolic events and coronary death. So far it is not known how HPR aff...

    Jonathan Rilinger, Melanie Meyer… in Journal of Thrombosis and Thrombolysis (2016)